Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Heinemann

Showing results (21-30 of 185) with videos related to

Pageof 19
Sort By:
Anticancer Research|March 1, 1993
Phase II-study for treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrineU Jehn, V Heinemann
Annals of Hematology|March 1, 1993
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrineU Jehn, V Heinemann
Cancer Detection and Prevention|June 9, 1998
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyureaU Jehn, V Heinemann
Deutsche Medizinische Wochenschrift (1946)|June 4, 2008
[Oncology 2008]H-J Stemmler, V Heinemann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2020
Reply to 'Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?' by Evesque et alJ W Holch, V Heinemann
Onkologie|May 15, 2002
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two casesJ Stemmler, V Heinemann, A Schalhorn
Der Internist|August 1, 1992
[Pancytopenia following non-A, non-B hepatitis]T Lorenz, V Heinemann, U Jehn
International Journal of Clinical Pharmacology, Therapy, and Toxicology|April 1, 1984
Serum lipoproteins and lecithin: cholesterol acyltransferase (LCAT) activity in hypercholesterolemic subjects given beta-sitosterolP Weisweiler, V Heinemann, P Schwandt
Frontiers of Radiation Therapy and Oncology|January 5, 2002
Gemcitabine (Gemzar) and radiotherapy--is it feasible?R Wilkowski, V Heinemann, C Stoffregen
MMW Fortschritte Der Medizin|June 17, 2005
[Tumor markers--how they should be applied]P Stieber, V Heinemann, A Schalhorn
Pageof 19

Showing results (21-30 of 185) with videos related to

Sort By:
Pageof 19
Anticancer Research|March 1, 1993
Phase II-study for treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrineU Jehn, V Heinemann
Annals of Hematology|March 1, 1993
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrineU Jehn, V Heinemann
Cancer Detection and Prevention|June 9, 1998
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyureaU Jehn, V Heinemann
Deutsche Medizinische Wochenschrift (1946)|June 4, 2008
[Oncology 2008]H-J Stemmler, V Heinemann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2020
Reply to 'Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?' by Evesque et alJ W Holch, V Heinemann
Onkologie|May 15, 2002
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two casesJ Stemmler, V Heinemann, A Schalhorn
Der Internist|August 1, 1992
[Pancytopenia following non-A, non-B hepatitis]T Lorenz, V Heinemann, U Jehn
International Journal of Clinical Pharmacology, Therapy, and Toxicology|April 1, 1984
Serum lipoproteins and lecithin: cholesterol acyltransferase (LCAT) activity in hypercholesterolemic subjects given beta-sitosterolP Weisweiler, V Heinemann, P Schwandt
Frontiers of Radiation Therapy and Oncology|January 5, 2002
Gemcitabine (Gemzar) and radiotherapy--is it feasible?R Wilkowski, V Heinemann, C Stoffregen
MMW Fortschritte Der Medizin|June 17, 2005
[Tumor markers--how they should be applied]P Stieber, V Heinemann, A Schalhorn
Pageof 19